Lucid Diagnostics (NASDAQ: LUCD) — Company Overview, News & Financial Data
Lucid Diagnostics develops non-invasive tests for early esophageal cancer detection, aiming to improve patient outcomes.
Lucid Diagnostics
Lucid Diagnostics (NASDAQ:LUCD) specializes in developing and commercializing innovative and non-invasive diagnostic tests for early detection of esophageal cancer, a critical focus given the growing prevalence of this condition. The company is dedicated to transforming the landscape of esophageal health by offering accessible and reliable solutions aimed at identifying precancerous conditions before they evolve into more severe stages. With a strong commitment to research and innovation, Lucid Diagnostics is actively involved in advancing its portfolio of diagnostic tools, with projects aimed at expanding usage and improving the accuracy of esophageal cancer detection. The company's objective is to significantly reduce the mortality rate associated with esophageal cancer by making early detection more common, aiding in the timely treatment and management of the disease.
Snapshot
Operations
Products and/or services of Lucid Diagnostics
- EsoGuard, a DNA test designed to detect esophageal precancerous conditions with high sensitivity.
- EsoCheck, a non-invasive, office-based procedure used alongside EsoGuard for sampling of esophageal cells.
- EsoCure, an esophageal ablation device with pending FDA approval aimed at treating precancerous esophageal conditions.
- LucidDx Labs, a dedicated laboratory service that processes EsoGuard and other diagnostic tests.
- Research partnerships focused on advancing the detection and treatment of esophageal diseases, including precancerous conditions.
- Educational initiatives aimed at raising awareness about the risks of esophageal cancer and the importance of early detection.
Lucid Diagnostics executive team
- Lishan AklogChairman & CEO
- Shaun M. O'NeillPresident & COO
- Dennis M. McGrathChief Financial Officer
- Michael Adam GordonGeneral Counsel & Secretary
- Sanford D. MarkowitzCo-Founder & Strategic Advisor
- Joseph WillisCo-founder & Strategic Advisor
- Amitabh ChakCo-Founder & Strategic Advisor
- Helen MoinovaCo-Founder & Strategic Advisor
- Brian J. deGuzmanChief Technology & Compliance Officer
- Suman M. VermaSenior VP & Chief Scientific Officer
Latest news about Lucid Diagnostics
Key financials
Reported results for Lucid Diagnostics, in USD.
- Market cap
- 77.6M
- Revenue (TTM)
- 5.4M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.4
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 4.7M | -49.6M | -58M | |
| 4.3M | -46.1M | -45.5M | |
| 2.4M | -48.5M | -52.7M | |
| 377K | -56.2M | -56.2M |